Janus kinase inhibitor cycling may be more effective than switching to bDMARDs among patients with RA who had an inadequate response to initial JAK inhibitor therapy.

The leading Cutaneous Squamous Cell Carcinoma Companies such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, ...

So we delivered another strong year with 2024 total revenues growing 15% versus 2023 to reach $4.2 billion, continuing the steady growth ... and our CDK2 inhibitor in ovarian cancer.

Here, the authors developed a cell-based screening assay for the identification of small molecule inhibitors of nonsense-mediated decay (NMD), and used it to validate KVS0001, a new small molecule ...

A study from the FIRST registry finds that rheumatoid arthritis patients with an inadequate response to JAK inhibitors may ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

Upadacitinib will face two main JAK inhibitor competitors – Eli Lilly’s Olumiant and Pfizer’s Xeljanz. Despite excitement surrounding the class, though, these treatments all face a complex ...

I-Mab (IMAB) stock gains as an early-stage trial for its gastric cancer therapy givastomig advances in a faster than expected ...